持田製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2024/01/31 | 3,305 | 3,350 | 3,290 | 3,350 | +35 | +1.1% | 25,400 |
2024/01/30 | 3,365 | 3,365 | 3,310 | 3,315 | -20 | -0.6% | 30,200 |
2024/01/29 | 3,320 | 3,345 | 3,320 | 3,335 | +15 | +0.5% | 25,800 |
2024/01/26 | 3,310 | 3,345 | 3,290 | 3,320 | +10 | +0.3% | 37,600 |
2024/01/25 | 3,280 | 3,310 | 3,275 | 3,310 | +25 | +0.8% | 29,400 |
2024/01/24 | 3,300 | 3,315 | 3,260 | 3,285 | -30 | -0.9% | 30,600 |
2024/01/23 | 3,325 | 3,360 | 3,315 | 3,315 | -10 | -0.3% | 29,100 |
2024/01/22 | 3,350 | 3,360 | 3,320 | 3,325 | -5 | -0.2% | 19,700 |
2024/01/19 | 3,325 | 3,345 | 3,320 | 3,330 | +5 | +0.2% | 19,300 |
2024/01/18 | 3,350 | 3,350 | 3,320 | 3,325 | -20 | -0.6% | 25,100 |
2024/01/17 | 3,380 | 3,410 | 3,345 | 3,345 | -35 | -1% | 36,300 |
2024/01/16 | 3,420 | 3,430 | 3,370 | 3,380 | -30 | -0.9% | 22,300 |
2024/01/15 | 3,380 | 3,420 | 3,370 | 3,410 | +50 | +1.5% | 23,500 |
2024/01/12 | 3,415 | 3,415 | 3,350 | 3,360 | -40 | -1.2% | 24,700 |
2024/01/11 | 3,400 | 3,410 | 3,375 | 3,400 | +10 | +0.3% | 31,100 |
2024/01/10 | 3,375 | 3,405 | 3,330 | 3,390 | +35 | +1% | 38,200 |
2024/01/09 | 3,310 | 3,365 | 3,310 | 3,355 | +45 | +1.4% | 26,800 |
2024/01/05 | 3,330 | 3,335 | 3,295 | 3,310 | -15 | -0.5% | 21,000 |
2024/01/04 | 3,270 | 3,325 | 3,230 | 3,325 | +55 | +1.7% | 33,600 |
2023/12/29 | 3,295 | 3,295 | 3,260 | 3,270 | -15 | -0.5% | 15,800 |
2023/12/28 | 3,290 | 3,290 | 3,250 | 3,285 | +15 | +0.5% | 17,400 |
2023/12/27 | 3,225 | 3,275 | 3,225 | 3,270 | +25 | +0.8% | 29,100 |
2023/12/26 | 3,255 | 3,270 | 3,235 | 3,245 | +5 | +0.2% | 29,400 |
2023/12/25 | 3,260 | 3,270 | 3,230 | 3,240 | -45 | -1.4% | 21,000 |
2023/12/22 | 3,265 | 3,290 | 3,260 | 3,285 | +45 | +1.4% | 18,100 |
2023/12/21 | 3,245 | 3,260 | 3,240 | 3,240 | -15 | -0.5% | 18,400 |
2023/12/20 | 3,225 | 3,270 | 3,225 | 3,255 | +25 | +0.8% | 21,100 |
2023/12/19 | 3,265 | 3,270 | 3,215 | 3,230 | -30 | -0.9% | 24,800 |
2023/12/18 | 3,245 | 3,265 | 3,215 | 3,260 | +5 | +0.2% | 26,200 |
2023/12/15 | 3,330 | 3,330 | 3,255 | 3,255 | -55 | -1.7% | 44,000 |
2023/12/14 | 3,335 | 3,335 | 3,290 | 3,310 | +10 | +0.3% | 21,600 |
2023/12/13 | 3,295 | 3,325 | 3,280 | 3,300 | +5 | +0.2% | 16,900 |
2023/12/12 | 3,330 | 3,340 | 3,290 | 3,295 | -5 | -0.2% | 14,900 |
2023/12/11 | 3,280 | 3,315 | 3,280 | 3,300 | +30 | +0.9% | 25,600 |
2023/12/08 | 3,315 | 3,330 | 3,250 | 3,270 | -80 | -2.4% | 43,900 |
2023/12/07 | 3,390 | 3,395 | 3,345 | 3,350 | -60 | -1.8% | 24,400 |
2023/12/06 | 3,380 | 3,425 | 3,365 | 3,410 | +60 | +1.8% | 69,000 |
2023/12/05 | 3,345 | 3,380 | 3,345 | 3,350 | -15 | -0.4% | 29,500 |
2023/12/04 | 3,365 | 3,375 | 3,330 | 3,365 | ±0 | ±0% | 28,900 |
2023/12/01 | 3,400 | 3,425 | 3,355 | 3,365 | +10 | +0.3% | 54,800 |
2023/11/30 | 3,315 | 3,355 | 3,255 | 3,355 | -25 | -0.7% | 136,200 |
2023/11/29 | 3,385 | 3,395 | 3,365 | 3,380 | -10 | -0.3% | 31,600 |
2023/11/28 | 3,350 | 3,395 | 3,345 | 3,390 | +55 | +1.6% | 33,800 |
2023/11/27 | 3,340 | 3,345 | 3,315 | 3,335 | +30 | +0.9% | 27,100 |
2023/11/24 | 3,285 | 3,310 | 3,270 | 3,305 | +10 | +0.3% | 23,200 |
2023/11/22 | 3,245 | 3,300 | 3,245 | 3,295 | +60 | +1.9% | 32,300 |
2023/11/21 | 3,195 | 3,240 | 3,195 | 3,235 | +40 | +1.3% | 25,800 |
2023/11/20 | 3,235 | 3,245 | 3,180 | 3,195 | -40 | -1.2% | 30,100 |
2023/11/17 | 3,200 | 3,240 | 3,200 | 3,235 | +45 | +1.4% | 28,400 |
2023/11/16 | 3,225 | 3,260 | 3,180 | 3,190 | -75 | -2.3% | 43,200 |
201~
250
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「持田薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
持田薬 | 331,500円 | +3.0% | +27.5% | 2.41% | 20.99倍 | 0.91倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 281,400円 | +52.1% | +23.3% | 0.00% | 19.98倍 | 3.83倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
鳥居薬 | 476,000円 | +12.0% | +28.1% | 2.52% | 26.24倍 | 1.11倍 |
|
JT傘下。柱の抗HIV薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム